ストックスクリーナーアプリを入手
39.07
2.57%
0.98
アフターアワーズ：
41.48
2.41
+6.17%
Soleno Therapeutics Inc (SLNO) 最新ニュース
Soleno Therapeutics (NASDAQ:SLNO) Given New $85.00 Price Target at TD Cowen - MarketBeat
Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com Nigeria
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year LowShould You Sell? - MarketBeat
Soleno Therapeutics Names New Chief Financial Officer - marketscreener.com
Soleno Therapeutics stock hits 52-week low at 36.01 USD - Investing.com
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Soleno Therapeutics names Jennifer Fulk as CFO - Investing.com
Soleno Therapeutics Appoints Jennifer Fulk As Chief Financial Officer - Nasdaq
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer - The Manila Times
Eli Lilly veteran Jennifer Fulk to lead finances at rare disease firm Soleno - Stock Titan
Soleno Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Soleno Therapeutics Announces New Chief Financial Officer Appointment - TipRanks
Biopharmaceutical company Soleno Therapeutics recently announced a major personnel appointment - Bitget
Soleno Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia
SLNO: VYKAT XR achieved rapid adoption, strong revenue, and profitability in its first year post-launch - TradingView
Soleno (SLNO) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations - Investing.com
Soleno Therapeutics (NASDAQ:SLNO) Announces Earnings Results - MarketBeat
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q4 Revenue $91.7M, vs. FactSet Est of $88.8M - marketscreener.com
Soleno Therapeutics Earnings Review: Q4 Summary - Benzinga
BRIEF-Soleno Therapeutics Q4 EPS USD 0.8 - TradingView
Soleno Therapeutics Reports Fourth Quarter and Full-Year - GlobeNewswire
Soleno Therapeutics faces earnings test as launch metrics scrutinized By Investing.com - Investing.com UK
Soleno Therapeutics faces earnings test as launch metrics scrutinized - Investing.com
Soleno Therapeutics to Announce Q4 Earnings on February 25 - Intellectia AI
What to Expect from Soleno Therapeutics's Earnings - Benzinga
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech Contender with 184% Upside Potential - DirectorsTalk Interviews
Will Soleno Therapeutics Inc. benefit from sector rotationEarnings Recap Summary & Weekly High Potential Stock Alerts - mfd.ru
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc - GuruFocus
CenterBook Partners LP Acquires 38,282 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Skandinaviska Enskilda Banken AB publ Increases Stock Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month LowHere's Why - MarketBeat
Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Readystate Asset Management LP Has $13.91 Million Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Commit To Purchase Soleno Therapeutics At $25, Earn 17.8% Annualized Using Options - Nasdaq
Wellington Management Group LLP Increases Stake in Soleno Therap - GuruFocus
Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance - Finviz
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Biotech Firm Surges with 200% Upside Potential - DirectorsTalk Interviews
(SLNO) Risk Channels and Responsive Allocation - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.52 Million Stake in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit - MarketBeat
Soleno Therapeutics stock hits 52-week low at 37.95 USD By Investing.com - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year LowTime to Sell? - MarketBeat
Is Soleno Therapeutics Inc. currently under institutional pressure2025 Key Lessons & Intraday High Probability Alerts - mfd.ru
SLNO: Strong market uptake, stable safety, and robust reimbursement support ongoing growth - TradingView
Why is Soleno Therapeutics Inc. stock going downGap Up & Safe Entry Trade Reports - mfd.ru
Why Soleno Therapeutics Inc. (6XC) stock is listed among top recommendationsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - mfd.ru
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET - The Manila Times
Soleno Therapeutics to Report Fourth Quarter and Full-Year - GlobeNewswire
Soleno Therapeutics prices $200M public offering - MSN
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Pullback Watch: Why is Soleno Therapeutics Inc. stock going downMarket Growth Report & Fast Moving Market Watchlists - baoquankhu1.vn
Why a biotech is drawing attention to a rare disease at the Super Bowl - Medical Marketing and Media
Soleno Therapeutics (NASDAQ:SLNO) Lowered to "Hold" Rating by Zacks Research - MarketBeat
(SLNO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Soleno Therapeutics (SLNO)'s VYKAT XR Momentum and 2025 Outlook Could Mean For Shareholders - Sahm
VYKAT XR Launch Momentum Could Be A Game Changer For Soleno Therapeutics (SLNO) - Yahoo Finance
1.18%
0.45%
大文字化:
|
ボリューム (24 時間):